Lisata Therapeutics, Inc. (LSTA) Stock Score, Valuation & Financial Research

Lisata Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LSTA

Lisata Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.21. These figures are a research snapshot, not a buy or sell recommendation.

What Lisata Therapeutics, Inc. does

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Lisata Therapeutics is a clinical-stage pharmaceutical company that generates no product revenue. Its business model focuses on the research, development, and potential future commercialization of innovative therapies for solid tumors and other serious diseases, currently funded through capital raises and cash reserves.

Products and services

  • The company's primary product candidate is certepetide, an investigational cyclic peptide drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively.

Brands and product families

  • certepetide — Lead investigational cyclic peptide product candidate. Source

Annual revenue by business

  • Reportable Segment: USD 170,000 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Business relationships and partnerships

  • GATC Health — A strategic alliance to exploit GATC Health's Multiomics Advanced Technology artificial intelligence drug discovery platform. Source

Business strengths to evaluate

  • Proprietary CendR platform technology Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single product candidate, certepetide Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source · Reportable Segment · GATC Health

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LSTA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.21
Market capitalization:
11.02M (currency not supplied)
Revenue:
USD 100K
Net income:
USD -14.62M
Free cash flow:
USD -15.98M
Cash:
USD 10.44M
Total debt:
USD 0.00
EPS:
USD -1.64

What stands out

  • Reported year-over-year revenue growth is -41.2%.
  • Free cash flow is USD -15.98M, negative for the stored period.
  • The balance sheet shows USD 10.44M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.44M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LSTA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving LSTA's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can LSTA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LSTA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LSTA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LSTA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research LSTA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.